Quick Answer
EXOZYMES INC. reported Total Revenue of $70.1 thousand for fiscal year 2023.
EXOZYMES INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | — | — | $70.1K | — |
| Revenue (ASC 606) | — | — | $70.1K | — |
| Net Income | -$9.16M -56.3% |
-$5.86M -187.5% |
-$2.04M | — |
| Diluted EPS | -$1.09 -22.5% |
-$0.89 -169.7% |
-$0.33 | — |
| Total Assets | $5.97M -54.2% |
$13.03M +266.3% |
$3.56M | — |
| Cash and Equivalents | $3.04M -68.7% |
$9.72M +14508.3% |
$66.5K | — |
| Stockholders Equity | $3.40M -67.4% |
$10.42M +2811.5% |
-$384.3K -128.0% |
$1.37M |
| R&D Expense | $3.71M +98.4% |
$1.87M +254.3% |
$527.5K | — |
| Operating Income | -$9.72M -63.8% |
-$5.93M -230.3% |
-$1.80M | — |
| Shares Outstanding | 8.41M +0.5% |
8.37M +33.9% |
6.25M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.29M | -38.1% | +3.1% |
| Diluted EPS | September 30, 2025 | -$0.27 | +0.0% | +3.6% |
| Total Assets | September 30, 2025 | $7.72M | +116.8% | -20.2% |
| Cash and Equivalents | September 30, 2025 | $5.10M | +2079.5% | -27.0% |
| Stockholders Equity | September 30, 2025 | $5.37M | +249.2% | -25.7% |
| R&D Expense | September 30, 2025 | $1.22M | +68.2% | +51.5% |
| Operating Income | September 30, 2025 | -$2.52M | -56.5% | +1.0% |
| Shares Outstanding | September 30, 2025 | 8.39M | +34.1% | +0.0% |
- EXOZYMES INC. reported Total Revenue of $70.1 thousand for fiscal year 2023.
- EXOZYMES INC. reported Revenue (ASC 606) of $70.1 thousand for fiscal year 2023.
- EXOZYMES INC. reported Net Income of -$9.16 million for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -56.3% in Net Income compared to the prior fiscal year.
- EXOZYMES INC. reported Diluted EPS of $1.09 per share (loss) for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -22.5% in Diluted EPS compared to the prior fiscal year.
- EXOZYMES INC. reported Total Assets of $5.97 million for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -54.2% in Total Assets compared to the prior fiscal year.
- EXOZYMES INC. reported Cash and Equivalents of $3.04 million for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -68.7% in Cash and Equivalents compared to the prior fiscal year.
- EXOZYMES INC. reported Stockholders Equity of $3.40 million for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -67.4% in Stockholders Equity compared to the prior fiscal year.
- EXOZYMES INC. reported R&D Expense of $3.71 million for fiscal year 2025.
- EXOZYMES INC. showed an increase of +98.4% in R&D Expense compared to the prior fiscal year.
- EXOZYMES INC. reported Operating Income of -$9.72 million for fiscal year 2025.
- EXOZYMES INC. showed a decrease of -63.8% in Operating Income compared to the prior fiscal year.
- EXOZYMES INC. reported Shares Outstanding of 8.41 million shares for fiscal year 2025.
- EXOZYMES INC. showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: